RxDoctor Payments Data

Elma Gacoscos, APRN

Family · Flint, MINPI 1255649919

Payments from drug & device makers

$2,227in general payments, 2019–2025

Across 49 payments — averaging $45.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • KCI USA, Inc.$981
  • Smith+Nephew$375
  • AstraZeneca$143
  • Sage Therapeutics, LLC$120
  • Abiomed$105
  • Medline Industries LP$86
  • plus $416 from 10 others

What the payments were for

  • Travel & lodging$59327%
  • Food & beverage$1,63473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,227 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$8,710
Medicare patients
55
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$32,635
JardianceEmpagliflozin16$17,376
SantylCollagenase Clostridium Hist.12$15,470
JanuviaSitagliptin Phosphate16$9,812
EliquisApixaban16$8,917
Albuterol Sulfate HfaAlbuterol Sulfate59$2,011
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,908
LantusInsulin Glargine,hum.Rec.Anlog28$1,651
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen104$1,128
Atorvastatin Calcium80$1,005
Novolin RInsulin Regular, Human17$754
Silver Sulfadiazine16$471
Nifedipine ErNifedipine15$462
Lisinopril48$424
Amlodipine Besylate57$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$375$15,47012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →